Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH)

NCT01822418 is registered in ClinicalTrials.gov with Central Institute of Mental Health, Mannheim as lead sponsor.

NCT NCT01822418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH)
Lead sponsor
Central Institute of Mental Health, Mannheim
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2013
Completion date
December 31, 2015
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

delusional disorder, schizoaffective disorder, schizophrenia